Reon1 is incorrect unfortunately.
Priority Review Vouchers are granted to rare paediatric indications by the FDA. They are not granted for adult orphan drug indications in the US.
Also, Presendin is Invex's GLP-1 exendin formulation for IIH. Given that the ODD will be for a GLP-1, Invex will simply reformulate Exendin for TBI. This will be a new formulation and can therefore satisfy the ODD for TBI.
In other words, this is not a backup orphan drug designation. Invex can achieve orphan drug approvals for both IIH and TBI, for different GLP-1 reformulations.
- Forums
- ASX - By Stock
- Ann: Invex Granted European Orphan Drug Designation for TBI
Reon1 is incorrect unfortunately. Priority Review Vouchers are...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.012M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 28219 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.6¢ | 2202 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 28219 | 0.080 |
1 | 100000 | 0.072 |
1 | 32000 | 0.060 |
1 | 60001 | 0.043 |
2 | 100001 | 0.038 |
Price($) | Vol. | No. |
---|---|---|
0.086 | 2202 | 1 |
0.090 | 126146 | 1 |
0.095 | 100000 | 1 |
0.100 | 76646 | 2 |
0.110 | 100000 | 1 |
Last trade - 16.12pm 03/05/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
Day chart unavailable